IDEAYA Biosciences Inc. announced positive results from its Phase 1/2 clinical trial (OptimUM-01) evaluating the combination of darovasertib and crizotinib in first-line treatment of metastatic uveal melanoma. The combination demonstrated a median overall survival of 21.1 months, compared to a historical median overall survival of approximately 12 months reported in published meta-analyses for this setting. Additional results included a median progression free survival of 7.0 months, an overall response rate of 34% by RECIST 1.1, a median duration of response of 9 months, and a disease control rate of 90%. The company is also conducting the registration-enabling Phase 2/3 OptimUM-02 trial in first-line HLA*A2:01-negative metastatic uveal melanoma and anticipates reporting median progression free survival data from this trial by year-end 2025 to Q1 2026 to support a potential U.S. accelerated approval filing. The summary of the data was presented at the 2025 Society for Melanoma Research Congress, and a presentation summary will be available on the Investor Relations section of IDEAYA's website.